Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.6K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Adult Stem Cells01:33

Adult Stem Cells

33.9K
Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.9K
Embryonic Stem Cells00:58

Embryonic Stem Cells

32.5K
Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.5K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

28.1K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.1K
Aging01:26

Aging

705
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
705

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LDLR-OPN Interaction Drives COVID-19 Myocarditis Through Monocyte Recruitment.

JACC. Basic to translational science·2026
Same author

Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty.

Cell stem cell·2026
Same author

Design and rationale of CATO, a Phase IIA, randomized, double-blind, placebo-controlled study of single or repeated intravenous administration of umbilical cord-derived mesenchymal stromal cells in ischemic cardiomyopathy.

American heart journal·2025
Same author

Phase I Randomized Study of Cardiac Stem Cells in Patients With Hypoplastic Left Heart Syndrome: The CHILD Trial.

JACC. Heart failure·2025
Same author

Targeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide.

Cell death discovery·2025
Same author

Cerebral vascular tortuosity and aneurysm formation and rupture: a novel vessel tortuosity scale.

Experimental neurology·2025

Related Experiment Video

Updated: Feb 1, 2026

Frailty Assessment in an Aging Mouse Model
06:58

Frailty Assessment in an Aging Mouse Model

Published on: September 23, 2025

597

Mesenchymal Stem Cell Therapy for Aging Frailty.

Ivonne Hernandez Schulman1,2, Wayne Balkan1, Joshua M Hare1

  • 1Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, United States.

Frontiers in Nutrition
|December 1, 2018
PubMed
Summary

Mesenchymal stem cells (MSCs) offer a potential treatment for frailty, a geriatric syndrome linked to chronic inflammation. This study found intravenously delivered MSCs safe and effective in improving physical function and reducing inflammation in frail elderly individuals.

Keywords:
cell transplantationgeriatricsimmunosenescenceinflammationregenerative medicine

More Related Videos

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

17.1K
Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
09:34

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy

Published on: May 18, 2017

8.0K

Related Experiment Videos

Last Updated: Feb 1, 2026

Frailty Assessment in an Aging Mouse Model
06:58

Frailty Assessment in an Aging Mouse Model

Published on: September 23, 2025

597
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

17.1K
Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
09:34

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy

Published on: May 18, 2017

8.0K

Area of Science:

  • Gerontology
  • Regenerative Medicine
  • Immunology

Background:

  • Frailty syndrome is a geriatric condition characterized by physiological decline, increasing risks of adverse health outcomes.
  • Frailty is linked to chronic inflammation and impaired tissue repair, with no specific therapies currently available.
  • Allogeneic mesenchymal stem cells (MSCs) show promise in tissue repair and immunomodulation.

Purpose of the Study:

  • To investigate the safety and efficacy of allogeneic mesenchymal stem cells (MSCs) in treating elderly individuals with frailty.
  • To evaluate the impact of MSC therapy on physical performance and inflammatory biomarkers in frail patients.

Main Methods:

  • A randomized, double-blinded, dose-finding study was conducted.
  • Elderly, frail individuals received intravenous infusions of allogeneic MSCs.
  • Physical performance measures and inflammatory biomarkers were assessed.

Main Results:

  • Intravenously delivered allogeneic MSCs were found to be safe in elderly, frail individuals.
  • Significant improvements in physical performance measures were observed.
  • Significant reductions in inflammatory biomarkers were noted, suggesting a potential therapeutic target.

Conclusions:

  • Frailty may be a treatable condition using cell therapy.
  • Targeting the link between frailty and chronic inflammation with MSCs is a promising therapeutic strategy.